By Dr Charlotte Rose Lemech

Book Chapters

Lemech CR; Kristeleit R; Arkenau HT, 2011, 'Novel Oncology Drug Development Strategies in the Era of Personalised Medicine', in Kapetanovic IM (ed.), Drug Discovery and Development - Present and Future

Journal articles

Hayes AG; Jonker B; Teng C; Lemech C; Killen AJ; Sim HW; McCormack AI, 2024, 'Approach to the Patient: New Era Emerges for Craniopharyngioma Management', Journal of Clinical Endocrinology and Metabolism, 109, pp. 2986 - 2996, http://dx.doi.org/10.1210/clinem/dgae503

Lemech CR; Zuniga R; Barve MA; Song Y; Zhang J; Zhou K; Zhang L; Shen L; Bishnoi S; Cherng H-JJ; Zhou C; Li W; Wang J; Zhu X; Zhu D; Li F; Shen Z; Yang J, 2024, 'A phase 1a/b, multi-regional, first-in-human study of CS5001, a novel anti-ROR1 ADC, in patients with advanced solid tumors and lymphomas.', Journal of Clinical Oncology, 42, pp. 3023 - 3023, http://dx.doi.org/10.1200/jco.2024.42.16_suppl.3023

Armstrong AJ; Geva R; Chung HC; Lemech C; Miller WH; Hansen AR; Lee JS; Tsai F; Solomon BJ; Kim TM; Rolfo C; Giranda V; Ren Y; Liu F; Kandala B; Freshwater T; Wang JS, 2024, 'Correction to: CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial(Investigational New Drugs, (2024), 42, (145-159), 10.1007/s10637-023-01410-2)', Investigational New Drugs, 42, pp. 340 - 341, http://dx.doi.org/10.1007/s10637-024-01444-0

Wahlroos S; Teng C; Tran B; Voskoboynik M; Gan HK; Spencer A; Kudva A; Song M; Lynch K; Yu Z; Desai J; Lemech CR, 2024, 'Results of a first-in-human, dose-escalation phase 1 study of the ERK1/2 inhibitor ATG-017 in patients with advanced solid tumors.', Journal of Clinical Oncology, 42, pp. e15114 - e15114, http://dx.doi.org/10.1200/jco.2024.42.16_suppl.e15114

Frentzas S; Mislang ARA; Lemech C; Nagrial A; Underhill C; Wang W; Wang ZM; Li B; Xia Y; Coward JIG, 2024, 'Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors', Journal for ImmunoTherapy of Cancer, 12, http://dx.doi.org/10.1136/jitc-2023-008037

Dorff T; Horvath LG; Autio K; Bernard-Tessier A; Rettig MB; Machiels JP; Bilen MA; Lolkema MP; Adra N; Rottey S; Greil R; Matsubara N; Tan DSW; Wong A; Uemura H; Lemech C; Meran J; Yu Y; Minocha M; McComb M; Penny HL; Gupta V; Hu X; Jurida G; Kouros-Mehr H; Janat-Amsbury MM; Eggert T; Tran B, 2024, 'A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer', Clinical Cancer Research, 30, pp. 1488 - 1500, http://dx.doi.org/10.1158/1078-0432.CCR-23-2978

Atkinson VG; Antras JF; Bedard P; Brenner W; Brown J; Lemech CR; Lloyd P; Margolin K; Mathew M; Park JJ; Thomas S; Twardowski P; Gardner H; Prawira A; Coello M; Ebrahimimizadeh W; To MD; Merchant R; Karanam SM; Yavari A; Siu LL; Tawbi HA; Ascierto PA, 2024, 'Abstract CT259: Results from monotherapy dose escalation of MDNA11, a long-acting IL-2 superkine, in a phase 1/2 trial show evidence of single-agent activity in advanced solid tumors', Cancer Research, 84, pp. CT259 - CT259, http://dx.doi.org/10.1158/1538-7445.am2024-ct259

Armstrong AJ; Geva R; Chung HC; Lemech C; Miller WH; Hansen AR; Lee JS; Tsai F; Solomon BJ; Kim TM; Rolfo C; Giranda V; Ren Y; Liu F; Kandala B; Freshwater T; Wang JS, 2024, 'CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial', Investigational New Drugs, 42, pp. 145 - 159, http://dx.doi.org/10.1007/s10637-023-01410-2

Tran B; Voskoboynik M; Bendell J; Gutierrez M; Lemech C; Day D; Frentzas S; Garrido-Laguna I; Standifer N; Wang F; Ferte C; Wang Y; Das M; Carneiro BA, 2024, 'A phase 1 study of the CD40 agonist MEDI5083 in combination with durvalumab in patients with advanced solid tumors', Immunotherapy, 16, pp. 759 - 774, http://dx.doi.org/10.1080/1750743X.2024.2359359

Lemech C; Sun Y; Nagrial A; Wu X; Morris M; Ning F; Yang J; Pan Y; Cai J; Lu P; Zhang T; Qiu F; Hu C; Zhang M; Liu Z; Han G; Nie J; Teng C; Zhou H; Day D, 2024, '345MO IBI354 (anti-HER2 antibody-drug conjugate [ADC]) in patients (pts) with advanced solid tumors and breast cancer (BC): Results from a phase I study', Annals of Oncology, 35, pp. S360 - S360, http://dx.doi.org/10.1016/j.annonc.2024.08.293

Gong J; Lemech C; Day D; Shan J; Morris M; Nagrial A; Chen M; Huang X; Zong H; Wang N; Yang Y; Yi T; Li W; Zhuang Z; Li Z; Liu Z; Luo Y; Zhang Y; Zhou H; Shen L, 2024, '576P Safety and efficacy of IBI354 (anti-HER2 ADC) in patients (pts) with advanced gastrointestinal (GI) cancers: Results from a phase I study', Annals of Oncology, 35, pp. S467 - S468, http://dx.doi.org/10.1016/j.annonc.2024.08.645

Lemech C; Kichenadasse G; Teng C; Nagrial A; Richardson G; Humphries TG; Killen AJ; Joshua A; Liu JJ; Churchill M; Barnett M; Cioffi M; Cosman R, 2024, '676TiP MYE Symphony: A first-in-human study to investigate the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the in vivo mRNA CAR therapy, MT-302, targeting TROP2 in adults with advanced epithelial tumors', Annals of Oncology, 35, pp. S528 - S528, http://dx.doi.org/10.1016/j.annonc.2024.08.742

Lemech C; Luke JJ; Falchook GS; Mckean M; Kichenadasse G; Teng C; Vandross AL; Salkeni MA; Atkinson VG; Liu JJ; Kennedy AM; Clark J; Ryan M; Schmidt-Kittler O; Steinhubel D; Wages D; Komarnitsky P; Puzanov I, 2024, '678TiP A phase I, first-in-human, dose escalation and expansion study of oral pan-RAF/MEK molecular glue NST-628 in subjects with solid tumors harboring RAS-MAPK pathway alterations', Annals of Oncology, 35, pp. S528 - S529, http://dx.doi.org/10.1016/j.annonc.2024.08.744

Lee S-H; Han J-Y; Lee KH; Lee G-W; Lemech C; Millward M; Roohullah A; Le X; Park K; Choi JY; Kim NY; Im S; Rajasekaran N; Park KE; Lee S; Moon H; Hwang S; Shin Y; Lee DH, 2023, 'Abstract B042: Efficacy and safety outcomes of ABN401 in NSCLC patients with MET Exon 14 Skipping: A clinically relevant subgroup analysis', Molecular Cancer Therapeutics, 22, pp. B042 - B042, http://dx.doi.org/10.1158/1535-7163.targ-23-b042

Day D; Park JJ; Coward J; Markman B; Lemech C; Kuo JC; Prawira A; Brown MP; Bishnoi S; Kotasek D; Strother RM; Cosman R; Su R; Ma Y; Yue Z; Hu HH; Wu R; Li P; Tse AN, 2023, 'A first-in-human phase 1 study of nofazinlimab, an anti-PD-1 antibody, in advanced solid tumors and in combination with regorafenib in metastatic colorectal cancer', British Journal of Cancer, 129, pp. 1608 - 1618, http://dx.doi.org/10.1038/s41416-023-02431-7

Wynne CJ; Cole A; Lemech C; Wang G; Zhang Y; Chen B; Wang M; Li B; Xia M; Sinclair R, 2023, 'Safety, Pharmacokinetics and Preliminary Efficacy of IL4-Rα Monoclonal Antibody AK120 in Both Healthy and Atopic Dermatitis Subjects: A Phase I, Randomized, Two-Part, Double-Blind, Placebo-Controlled, Dose-Escalation, First-In-Human Clinical Study', Dermatology and Therapy, 13, pp. 2357 - 2373, http://dx.doi.org/10.1007/s13555-023-01010-1

Fries L; Formica N; Mallory RM; Zhou H; Plested JS; Kalkeri R; Moldovan I; Patel N; Albert G; Robinson M; Cho I; Chau G; Dubovsky F; Glenn GM; Adams M; Arya M; Athan E; Berger I; Bradley P; Glover R; Griffin P; Kim J; Kitchener S; Klein T; Leah A; Lemech C; Lickliter J; Manning MB; Napier-Flood F; Nugent P; Thackwray S; Turner M, 2023, 'Strong CD4⁺T-Cell Responses to Ancestral and Variant Spike Proteins Are Established by NVX-CoV2373 Severe Acute Respiratory Syndrome Coronavirus 2 Primary Vaccination', Journal of Infectious Diseases, 228, pp. 734 - 741, http://dx.doi.org/10.1093/infdis/jiad163

Lee DH; Han J-Y; Lemech CR; Millward M; Roohullah A; Choi JY; Park KE; Kim NY; Im S; Rajasekaran N; Lee S; Moon H; Hwang S; Shin YOUNGKEE; Lee S-H, 2023, 'ABN401 in patients with NSCLC with MET exon 14 (METex14) skipping: Result from the pilot expansion study.', Journal of Clinical Oncology, 41, pp. e21148 - e21148, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e21148

Lemech CR; Argent C; Scribner CL; Sharabi A; Daniels R; Appleman JR, 2023, 'Abstract CT180: Activation of innate and adaptive immune response with a clinical stage TLR7 agonist prodrug PRTX007', Cancer Research, 83, pp. CT180 - CT180, http://dx.doi.org/10.1158/1538-7445.am2023-ct180

Fu S; Falchook GS; Barve M; McKean M; Tan TJ; Lemech C; Chee CE; Marina N; Abbadessa G; Meng R; Rotolo F; Wang H; Deng J; Wang W; Wang R; Meniawy T, 2023, 'Abstract 2155: Joint modeling of safety and peripheral mode-of-action (MoA) biomarkers to support RP2D identification in Phase 1 study of SAR444245 (SAR’245) as monotherapy (mono) or combined with pembrolizumab (pembro) in patients with advanced solid tumors', Cancer Research, 83, pp. 2155 - 2155, http://dx.doi.org/10.1158/1538-7445.am2023-2155

Lemech CR; Kichenadasse G; Marschner JP; Alevizopoulos K; Otterlei M; Millward M, 2023, 'ATX-101, a cell-penetrating protein targeting PCNA, can be safely administered as intravenous infusion in patients and shows clinical activity in a Phase 1 study', Oncogene, 42, pp. 541 - 544, http://dx.doi.org/10.1038/s41388-022-02582-6

Lemech C; Dredge K; Bampton D; Hammond E; Clouston A; Waterhouse NJ; Stanley AC; Leveque-El Mouttie L; Chojnowski GM; Haydon A; Pavlakis N; Burge M; Brown MP; Goldstein D, 2023, 'Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors', Journal for ImmunoTherapy of Cancer, 11, http://dx.doi.org/10.1136/jitc-2022-006136

Strickler JH; Satake H; George TJ; Yaeger R; Hollebecque A; Garrido-Laguna I; Schuler M; Burns TF; Coveler AL; Falchook GS; Vincent M; Sunakawa Y; Dahan L; Bajor D; Rha SY; Lemech C; Juric D; Rehn M; Ngarmchamnanrith G; Jafarinasabian P; Tran Q; Hong DS, 2023, 'Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer', New England Journal of Medicine, 388, pp. 33 - 43, http://dx.doi.org/10.1056/NEJMoa2208470

Tran B; Millward M; Lemech C; Frentzas S; Day D; Latifi A; Desai J; Wabnitz P; Kearney P; Galkin A, 2023, '1047P AXA-042, a systemically administered TLR2/6 agonist, demonstrates target engagement and TLR pathway activation in patients with advanced solid tumors', Annals of Oncology, 34, pp. S635 - S635, http://dx.doi.org/10.1016/j.annonc.2023.09.2186

Weickhardt AJ; Frentzas S; Lemech C; Srimani J; Yin J; Trepicchio WL; Gorgun C; Kichenadasse G, 2023, '711TiP A phase I/II, first-in-human, open-label, dose-escalation study of TAK-186, an EGFR × CD3ε COBRA T cell engager, in adult patients with unresectable, locally advanced, or metastatic solid tumors', Annals of Oncology, 34, pp. S492 - S492, http://dx.doi.org/10.1016/j.annonc.2023.09.1897

Pimanda JE; Thoms JAI; Hampton HR; Davidson S; Joshi S; Sarowar CH; Lim XY; Nunez AC; Kakadia PM; Pickford R; Raftery M; Hough S; Buckland G; Bailey M; Ghodke Y; Absar N; Vaughan L; Pasalic L; Fong CY; Kenealy M; Hiwase D; Stoddart R; Mohammed S; Lee L; Passam FH; Spring K; Skarratt KK; Rebeiro P; Larsen SR; Presgrave P; Stevenson WS; Ling S; Tiley C; Fuller S; Roncolato F; Enjeti AK; Hoenemann D; Lemech C; Bohlander SK; Olivier J; Hertzberg M; Unnikrishnan A; Polizzotto MN, 2022, 'In Vivo Drug Incorporation and Intracellular Dynamics of Injectable Versus Oral Azacytidine: A Phase II Open Label Multicentre Trial', Blood, 140, pp. 6927 - 6929, http://dx.doi.org/10.1182/blood-2022-157634

Mallory RM; Formica N; Pfeiffer S; Wilkinson B; Marcheschi A; Albert G; McFall H; Robinson M; Plested JS; Zhu M; Cloney-Clark S; Zhou B; Chau G; Robertson A; Maciejewski S; Hammond HL; Baracco L; Logue J; Frieman MB; Smith G; Patel N; Glenn GM; Adams M; Arya M; Athan E; Berger I; Bradley P; Briskin T; Glover R; Griffin P; Kim J; Kitchener S; Klein T; Leah A; Leelasena I; Lemech C; Lickliter J; Manning MB; Napier-Flood F; Nugent P; Thackwray S; Turner M, 2022, 'Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial', The Lancet Infectious Diseases, 22, pp. 1565 - 1576, http://dx.doi.org/10.1016/S1473-3099(22)00420-0

Lemech C; Argent C; Scribner C; Daniels R; Appleman JR, 2022, 'Abstract CT189: PRTX007, an optimized TLR7 agonist for systemic immunotherapy of cancers: Interim analysis of phase I study in healthy volunteers', Cancer Research, 82, pp. CT189 - CT189, http://dx.doi.org/10.1158/1538-7445.am2022-ct189

Wynne C; Schwabe C; Lemech C; Stroissnig H; Dias R; Sobierska J; Guenzi E; Otto H; Sattar A; Kay R; Haliduola HN; Berti F, 2022, 'A randomized, adaptive design, double-blind, 3-arm, parallel study assessing the pharmacokinetics and safety of AVT02, a high-concentration (100 mg/mL) Adalimumab biosimilar, in healthy adult subjects (ALVOPAD FIRST)', Expert Opinion on Investigational Drugs, 31, pp. 965 - 976, http://dx.doi.org/10.1080/13543784.2022.2035359

Falchook GS; Fu S; Lemech C; Mckean MA; Azad AA; Gan HK; Sommerhalder D; Wang JS; Tan TJY; Chee CE; Barve M; Moser J; Mooney J; Acuff N; Wang R; Marina N; Abbadessa G; Streit M; Ramusovic S; Meniawy T, 2022, '747P Phase I study of SAR444245 (SAR’245) as monotherapy (mono) and combined with pembrolizumab (pembro) or cetuximab (cetux) in patients (pts) with advanced solid tumors', Annals of Oncology, 33, pp. S885 - S886, http://dx.doi.org/10.1016/j.annonc.2022.07.873

Lee DH; Roohullah A; Cho BC; Lemech C; de Souza P; Millward M; Choi J; Park KE; Lee M; Kim Y; Park S; Lee J; Kim J; Shin YK; Han J-Y, 2021, 'Phase I dose-escalation study to evaluate safety and clinical activity of c-MET inhibitor ABN401 in patients with advanced solid tumor', ANNALS OF ONCOLOGY, 32, pp. S1029 - S1030, http://dx.doi.org/10.1016/j.annonc.2021.08.1958

Lickliter JD; Jennens R; Lemech CR; Kichenadasse G; Cai D; Su SY-C, 2021, 'Phase 1 dose-escalation study of ACT001 in patients with recurrent glioblastoma and other advanced solid tumors.', Journal of Clinical Oncology, 39, pp. 2037 - 2037, http://dx.doi.org/10.1200/jco.2021.39.15_suppl.2037

Coward J; Mislang ARA; Frentzas S; Lemech CR; Nagrial A; Jin X; Li B; Wang ZM; Kwek KY; Xia Y, 2021, 'Safety and efficacy of AK112, an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors in a phase I dose escalation study.', Journal of Clinical Oncology, 39, pp. 2515 - 2515, http://dx.doi.org/10.1200/jco.2021.39.15_suppl.2515

Lemech CR; Kichenadasse G; Marschner J-P; Alevizopoulos K; Otterlei M; Millward M, 2021, 'Safety profile and disease stabilization in late stage, heavily pretreated, solid tumor patients in a first-in-human (FIH) study of ATX-101, a drug targeting proliferating cell nuclear antigen (PCNA).', Journal of Clinical Oncology, 39, pp. 3067 - 3067, http://dx.doi.org/10.1200/jco.2021.39.15_suppl.3067

Lee DH; Roohullah A; Cho BC; Lemech CR; de Souza PL; Millward M; Choi JY; Park KE; Lee M; Kim Y; Shin Y; Han J-Y, 2021, 'Trial in progress: A phase 1-2 multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of ABN401 in patients with advanced solid tumors.', JOURNAL OF CLINICAL ONCOLOGY, 39, http://dx.doi.org/10.1200/JCO.2021.39.15_suppl.TPS3157

Coward J; Frentzas S; Mislang A; Gao B; Lemech C; Jin X; Li B; Wang M; Kwek KY; Zhou Y; Xia Y, 2021, '427 Efficacy and safety of AK112, an anti-PD-1/VEGF-A bispecific antibody, in patients with platinum-resistant/refractory epithelial ovarian cancer in a Phase 1 study', Regular and Young Investigator Award Abstracts, pp. A457 - A457, http://dx.doi.org/10.1136/jitc-2021-sitc2021.427

Lemech C; Woodward N; Chan N; Mortimer J; Naumovski L; Nuthalapati S; Tong B; Jiang F; Ansell P; Ratajczak CK; Sachdev J, 2020, 'A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors', Investigational New Drugs, 38, pp. 1815 - 1825, http://dx.doi.org/10.1007/s10637-020-00960-z

Perry N; Moss S; Dixon S; Milner S; Mokbel K; Lemech C; Arkenau HT; Duffy S; Pinker K, 2020, 'Mammographic breast density and urbanization: Interactions with BMI, environmental, lifestyle, and other patient factors', Diagnostics, 10, http://dx.doi.org/10.3390/diagnostics10060418

Coward J; Lemech CR; Mislang ARA; Parakh S; Underhill C; Nagrial A; Jin X; Li B; Wang ZM; Kwek KY; Xia Y, 2020, 'A phase I study of AK112, a bispecific antibody that targets PD-1 and VEGF co-expressing T cells, in patients with advanced solid tumors.', Journal of Clinical Oncology, 38, pp. TPS3155 - TPS3155, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.tps3155

Berry S; Giraldo N; Nguyen P; Green B; Xu H; Ogurtsova A; Soni A; Succaria F; Wang D; Roberts C; Stein J; Engle E; Pardoll D; Anders R; Cottrell T; Taube JM; Tran B; Voskoboynik M; Kuo J; Bang YL; Chung HC; Ahn MJ; Kim SW; Perera A; Freeman D; Achour I; Faggioni R; Xiao F; Ferte C; Lemech C; Meric-Bernstam F; Werner T; Hodi S; Messersmith W; Lewis N; Talluto C; Dostalek M; Tao A; McWhirter S; Trujillo D; Luke J; Xu C; Bomarelli B; Qi J; Qin G; Yu H; Jenkins M; Lo KM; Halle JP; Lan Y; Taylor M; Vogelzang N; Cohn A; Stepan D; Shumaker R; Dutcus C; Guo M; Schmidt E; Rasco D; Brose M; Di Simone C; Jain S; Richards D; Encarnacion C; Vogelzeng N; Mier J; An J; Yang YY; Lee WH; Yang J; Kim JK; Kim HG; Paek SH; Lee JW; Woo J; Kim JB; Kwon H; Lim W; Paik NS; Kim YK; Moon BI; Janku F; Tan D; Martin-Liberal J; Takahashi S; Geva R; Gucalp A; Chen X; Subramanian K; Mataraza J; Wheler J; Bedard P, 2019, 'Correction: 33rd Annual meeting & pre-conference programs of the Society for Immunotherapy of Cancer (SITC 2018) (Journal for ImmunoTherapy of Cancer (2018) 6:Suppl 1 DOI: 10.1186/s40425-018-0422-y)', Journal for ImmunoTherapy of Cancer, 7, http://dx.doi.org/10.1186/s40425-019-0519-y

Coward J; Lemech C; Meniawy T; Dupont CD; Gonzalez AM; Lim M; Savitsky D; Carini M; Hu S; Shebanova O; Dow E; Ortuzar W; Buell JS; Stein RB; Youssoufian H, 2018, 'Phase I/II study of CTLA-4 inhibitor AGEN1884 + PD-1 Inhibitor AGEN2034 in patients with advanced/refractory solid tumors, with expansion into 2L cervical cancer and solid tumors', Annals of oncology : official journal of the European Society for Medical Oncology, 29, pp. viii417, http://dx.doi.org/10.1093/annonc/mdy288.041

Lickliter JD; Jennens R; Lemech CR; Su SY-C; Chen Y, 2018, 'Phase 1 dose-escalation study of ACT001 in patients with recurrent glioblastoma and other advanced solid tumors', JOURNAL OF CLINICAL ONCOLOGY, 36, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.e14048

Mateo J; Ganji G; Lemech C; Burris HA; Han SW; Swales K; Decordova S; DeYoung MP; Smith DA; Kalyana-Sundaram S; Wu J; Motwani M; Kumar R; Tolson JM; Rha SY; Chung HC; Eder JP; Sharma S; Bang YJ; Infante JR; Yan L; De Bono JS; Arkenau HT, 2017, 'A first-time-in-human study of GSK2636771, a phosphoinositide 3 kinase beta-selective inhibitor, in patients with advanced solid tumors', Clinical Cancer Research, 23, pp. 5981 - 5992, http://dx.doi.org/10.1158/1078-0432.CCR-17-0725

Goldstein D; Lemech C; Valle J, 2017, 'New molecular and immunotherapeutic approaches in biliary cancer', ESMO Open, 2, pp. e000152, http://dx.doi.org/10.1136/esmoopen-2016-000152

Uccello M; Moschetta M; Mak G; Martynyuk N; Hauser J; Bassett S; Voskoboynik M; Lemech C; Rafii S; Arkenau H-T, 2017, 'BRAF +/- MEK inhibition in patients (pts) with BRAF-mutant (mut) metastatic colorectal cancer (mCRC): The Sarah Cannon Research Institute UK’s experience.', Journal of Clinical Oncology, 35, pp. 645 - 645, http://dx.doi.org/10.1200/jco.2017.35.4_suppl.645

Soria JC; Gan HK; Blagden SP; Plummer R; Arkenau HT; Ranson M; Evans TRJ; Zalcman G; Bahleda R; Hollebecque A; Lemech C; Dean E; Brown J; Gibson D; Peddareddigari V; Murray S; Nebot N; Mazumdar J; Swartz L; Auger KR; Fleming RA; Singh R; Millward M, 2016, 'A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors', Annals of Oncology, 27, pp. 2268 - 2274, http://dx.doi.org/10.1093/annonc/mdw427

Plesner T; Arkenau HT; Gimsing P; Krejcik J; Lemech C; Minnema MC; Lassen U; Laubach JP; Palumbo A; Lisby S; Basse L; Wang J; Sasser AK; Guckert ME; De Boer C; Khokhar NZ; Yeh H; Clemens PL; Ahmadi T; Lokhorst HM; Richardson PG, 2016, 'Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma', Blood, 128, pp. 1821 - 1828, http://dx.doi.org/10.1182/blood-2016-07-726729

Hughes A; Landers D; Arkenau HT; Shah S; Stephens R; Mahal A; Simmons M; Lemech C; Royle J, 2016, 'Erratum to: Development and Evaluation of a New Technological Way of Engaging Patients and Enhancing Understanding of Drug Tolerability in Early Clinical Development: PROACT (Adv Ther, (2016), 33, (1012-1024), 10.1007/s12325-016-0335-4)', Advances in Therapy, 33, pp. 1677 - 1678, http://dx.doi.org/10.1007/s12325-016-0390-x

Lemech CR; Williams R; Thompson SR; McCaughan B; Chin M, 2016, 'Treatment of breast cancer 2 (BRCA2)-mutant follicular dendritic cell sarcoma with a poly ADP-ribose polymerase (PARP) inhibitor: A case report', BMC Research Notes, 9, pp. 386, http://dx.doi.org/10.1186/s13104-016-2189-x

Back to profile page